---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-125073"
form_type: "8-K"
ticker: "MDXG"
cik: "0001376339"
company_name: "MIMEDX GROUP, INC."
filed_at: "2024-04-30T23:59:59+00:00"
generated_at: "2026-06-03T04:14:20.069967+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MiMedx Q1 net sales $85M (+18% YoY); GAAP net income $9M; Adj. EBITDA $19M (22% margin)

## Summary
- Net sales $85M, up 18% YoY; gross margin improved to 84.7% from 82.7%.
- GAAP net income $9M vs loss of $5M in prior year; Adjusted EBITDA $19M (22% margin) vs $5.5M (7.7%).
- Cash $48M at March 31, down from $82M at Dec 31, due to repaying $30M revolver and $5M TELA Bio payment.
- Signed distribution agreement with Regenity Biosciences for 510(k)-cleared collagen xenograft; launch expected later in 2024.
- Appointed two new independent directors; launched MIMEDX Connect online ordering platform.

## SEC filing metadata
- accession: 0001193125-24-125073
- form_type: 8-K
- ticker: MDXG
- cik: 0001376339
- company_name: MIMEDX GROUP, INC.
- filed_at: 2024-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1376339/000119312524125073/0001193125-24-125073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1376339/000119312524125073/d832294d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-125073
- JSON: https://secwatch.observer/filing/0001193125-24-125073.json
- Plain text: https://secwatch.observer/filing/0001193125-24-125073.txt

## Key facts
- Earnings Releases
  MIMEDX GROUP, INC. reported first quarter ended March 31, 2024 results: revenue Net Sales of $85 Million, net income GAAP Net Income was $9 Million.
  - Period: first quarter ended March 31, 2024
  - Revenue: Net Sales of $85 Million
  - Net income: GAAP Net Income was $9 Million
  - Result: reported results
  source text: MIMEDX Announces First Quarter 2024 Operating and Financial Results Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter First Quarter GAAP Net Income was $9 Million First Quarter Adjusted EBITDA of $19 Million, or 22% of Net Sales
  evidence_url: https://www.sec.gov/Archives/edgar/data/1376339/000119312524125073/0001193125-24-125073-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.